Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release.

Therapeutic agents based on DNA or RNA oligonucleotides (e.g., antisense DNA oligonucleotide, small interfering RNA) require a regulation of their kinetics in cytoplasm to maintain an optimal concentration during the treatment period. In this respect, delivery of functional nanoparticles containing these drugs into cytoplasm has been thought to have a potential for the cytosolic controlled gene release. In this study, we establish a protocol for the encapsulation of nanoparticles into liposome, which is further fused with ultra violet-inactivated Sendai virus to compose fusogenic liposomes. When nanoparticles were encapsulated in conventional liposomes, endocytosis-mediated uptake of nanoparticles was observed. In contrast, numerous amounts of nanoparticles were delivered into the cytoplasm without any cytotoxicity when the particles were encapsulated in fusogenic liposomes. Additionally, fusogenic liposome showed a high ability to deliver nanoparticles containing DNA oligonucleotides into cytoplasm. These results indicate that this combinatorial nanotechnology using fusogenic liposome and nanoparticle is a valuable system for regulating the intracellular pharmacokinetics of gene-based drugs.

[1]  Y. Yashiro‐Ohtani,et al.  Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway , 2000, European journal of immunology.

[2]  Koji Kariya-city Aichi-pref. Tanaka,et al.  A novel vaccine delivery system using immunopotentiating fusogenic liposomes. , 1999, Biochemical and biophysical research communications.

[3]  Teruo Okano,et al.  Preparation and Characterization of the Micelle-Forming Polymeric Drug Indomethacin-lncorporated Polyfethylene oxide)-Poly(β-benzyl L-aspartate) Block Copolymer Micelles , 1996 .

[4]  C Russell Middaugh,et al.  Barriers to nonviral gene delivery. , 2003, Journal of pharmaceutical sciences.

[5]  Vladimir P Torchilin,et al.  Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome–DNA complexes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  V. Torchilin,et al.  TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Y. Cho‐Chung.  Antisense DNAs as targeted genetic medicine to treat cancer , 2003, Archives of pharmacal research.

[8]  Jayanth Panyam,et al.  Rapid endo‐lysosomal escape of poly(DL‐lactide‐coglycolide) nanoparticles: implications for drug and gene delivery , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  K. Rock,et al.  Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. , 1997, Journal of immunology.

[10]  Y. Tsutsumi,et al.  Tumor necrosis factor alpha-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors. , 1998, Cancer research.

[11]  T. Mayumi,et al.  Efficient gene transfer into mammalian cells using fusogenic liposome. , 1996, Biochemical and biophysical research communications.

[12]  N. Pante,et al.  Nuclear pore complex is able to transport macromolecules with diameters of about 39 nm. , 2002, Molecular biology of the cell.

[13]  Kazunori Kataoka,et al.  PEGylated Nanoparticles for Biological and Pharmaceutical Applications , 2003 .

[14]  A. Eastman,et al.  Deoxyribonuclease II is a lysosomal barrier to transfection. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  Robert Langer,et al.  Moving smaller in drug discovery and delivery , 2002, Nature Reviews Drug Discovery.

[16]  M. Morris,et al.  A peptide carrier for the delivery of biologically active proteins into mammalian cells , 2001, Nature Biotechnology.

[17]  Y. Ogawa.  Injectable microcapsules prepared with biodegradable poly(alpha-hydroxy) acids for prolonged release of drugs. , 1997, Journal of biomaterials science. Polymer edition.

[18]  H. Kiyono,et al.  HIV Mucosal Vaccine: Nasal Immunization with gp160-Encapsulated Hemagglutinating Virus of Japan-Liposome Induces Antigen-Specific CTLs and Neutralizing Antibody Responses1 , 2003, The Journal of Immunology.

[19]  J. Alper.  Breaching the Membrane , 2002, Science.

[20]  Judy Lieberman,et al.  RNA interference targeting Fas protects mice from fulminant hepatitis , 2003, Nature Medicine.

[21]  H. Inokuchi,et al.  Gene transfer vectors based on Sendai virus. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Scott J Hollister,et al.  Delivery and protection of adenoviruses using biocompatible hydrogels for localized gene therapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  R. Duncan.  The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.

[24]  A. Gewirtz,et al.  Nucleic-acid therapeutics: basic principles and recent applications , 2002, Nature Reviews Drug Discovery.

[25]  Jean M. J. Fréchet,et al.  A macromolecular delivery vehicle for protein-based vaccines: Acid-degradable protein-loaded microgels , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Erkki Ruoslahti,et al.  Nanocrystal targeting in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  H Harashima,et al.  Biopharmaceutical evaluation of the liposomes prepared by rehydration of freeze-dried empty liposomes (FDELs) with an aqueous solution of a drug. , 1996, Biopharmaceutics & drug disposition.

[28]  Yang Shi,et al.  Small RNA: can RNA interference be exploited for therapy? , 2003, The Lancet.

[29]  M. Akashi,et al.  Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. , 2002, International journal of pharmaceutics.

[30]  H. Kiyono,et al.  Sendai Virus Fusion Protein-Mediates Simultaneous Induction of MHC Class I/II-Dependent Mucosal and Systemic Immune Responses Via the Nasopharyngeal-Associated Lymphoreticular Tissue Immune System1 , 2001, The Journal of Immunology.

[31]  R. Kole,et al.  Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  G. Hardee,et al.  Cytosolic delivery of antisense oligonucleotides by listeriolysin O-containing liposomes , 2003, Gene Therapy.

[33]  T. Mayumi,et al.  Application of fusogenic liposomes containing fragment A of diphtheria toxin to cancer therapy. , 1996, British Journal of Cancer.

[34]  H. Kiyono,et al.  Characterization of mucoadhesive microspheres for the induction of mucosal and systemic immune responses. , 2000, Vaccine.

[35]  S. Nakagawa,et al.  Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development. , 2001, Advanced drug delivery reviews.